Literature DB >> 11981840

CD2 physically associates with CD5 in rat T lymphocytes with the involvement of both extracellular and intracellular domains.

Mónica A A Castro1, Paula A Tavares, Mara S Almeida, Raquel J Nunes, Mark D Wright, Don Mason, Alexandra Moreira, Alexandre M Carmo.   

Abstract

T lymphocytes can be activated and induced to proliferate through stimulation of the CD2 glycoprotein with functional combinations of CD2 antibodies. However, this mechanism of signal transduction via CD2 is still not fully understood. We have investigated which molecules on the T cell surface preferentially associate in Cis with CD2 and may regulate its signaling properties. Though a quantification method we found that CD5 represents the antigen capable of co-precipitating a larger proportion of CD2. Using co-capping assays and immunoprecipitations from cell lysates, we show that an association between CD2 and CD5 can be found in rat thymocytes, T lymphocytes and in a thymoma cell line. Possibly, this interaction is a direct one, since CD2 and CD5 transiently expressed in Cos7 cells co-precipitate each other. Furthermore, using CD2 chimeric proteins containing different domains of CD2, expressed in Cos7 cells as well as in stably transfected Jurkat cells, we show that the interaction between CD2 and CD5 is held at both the intra- and extracellular levels, but does not involve the transmembrane domain. The fact that both the extracellular and the cytoplasmic domains of CD2 interact with CD5 suggests a specific and tight association between the two molecules, possibly relevant for the fine-tuning of signal transduction in T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981840     DOI: 10.1002/1521-4141(200205)32:5<1509::AID-IMMU1509>3.0.CO;2-T

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Lamina propria T cell activation: role of the costimulatory molecule CD2 and its cytoplasmic tail for the regulation of proliferation and apoptosis.

Authors:  Sven Henschke; Nina N Pawlowski; Martin K Wild; Anton J Kroesen; Martin Zeitz; Jörg C Hoffmann
Journal:  Int J Colorectal Dis       Date:  2005-08-23       Impact factor: 2.571

2.  A ligand for CD5 is CD5.

Authors:  Marion H Brown; Erica Lacey
Journal:  J Immunol       Date:  2010-10-15       Impact factor: 5.422

3.  A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase.

Authors:  Martina Bamberger; Ana Mafalda Santos; Carine M Gonçalves; Marta I Oliveira; John R James; Alexandra Moreira; Franscisco Lozano; Simon J Davis; Alexandre M Carmo
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

4.  Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Authors:  Ruby Alonso-Ramirez; Séverine Loisel; Caroline Buors; Jacques-Olivier Pers; Enrique Montero; Pierre Youinou; Yves Renaudineau
Journal:  Arthritis       Date:  2011-02-10

5.  CD6 attenuates early and late signaling events, setting thresholds for T-cell activation.

Authors:  Marta I Oliveira; Carine M Gonçalves; Mafalda Pinto; Stéphanie Fabre; Ana Mafalda Santos; Simon F Lee; Mónica A A Castro; Raquel J Nunes; Rita R Barbosa; Jane R Parnes; Chao Yu; Simon J Davis; Alexandra Moreira; Georges Bismuth; Alexandre M Carmo
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

6.  CD6 modulates thymocyte selection and peripheral T cell homeostasis.

Authors:  Marc Orta-Mascaró; Marta Consuegra-Fernández; Esther Carreras; Romain Roncagalli; Amado Carreras-Sureda; Pilar Alvarez; Laura Girard; Inês Simões; Mario Martínez-Florensa; Fernando Aranda; Ramón Merino; Vanesa-Gabriela Martínez; Rubén Vicente; Jesús Merino; Adelaida Sarukhan; Marie Malissen; Bernard Malissen; Francisco Lozano
Journal:  J Exp Med       Date:  2016-07-04       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.